The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
Drinking fell for the first time since COVID-19, but not for adults 50 to 64. Hepatologists explain what clinicians can do to close the gap.
News|Articles|June 27, 2025
Beyond Weight Bias: Lessons from a Patient’s Progression to Stage 4 MASH
Author(s)Lana Pine
This case study underscores how fragmented care and weight bias can contribute to late-stage MASH diagnosis.
Advertisement
Advertisement
For many clinicians, metabolic dysfunction-associated steatohepatitis (MASH) — formerly known as NASH — presents a diagnostic and management challenge. Dianne Gillard’s story, a U.K.-based patient advocate, highlights the real-world consequences of missed diagnostic opportunities and underscores the need for earlier detection, patient-centered communication, and system-wide changes in fatty liver disease screening.
Related to this article
As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Advertisement
Advertisement